7 Reversal Agents and Bleeding Management

Urgent management principles

For suspected major or life-threatening bleeding, urgently stop the suspected causative antithrombotic when appropriate. Stabilize airway, breathing, and circulation, control the bleeding source, and obtain needed blood products and specialist support.

Check blood count, coagulation tests, kidney function, and type and screen or crossmatch as appropriate. Identify the exact drug, last dose, and likely remaining drug effect. A normal routine clotting test does not rule out clinically important direct oral anticoagulant activity, and time-critical reversal should not be delayed for laboratory results when severe bleeding is evident.

Reversal agents and PCC can cause harm, including thrombosis. Reserve them for situations where the expected benefit justifies those risks.

Warfarin-associated bleeding

For life-threatening bleeding associated with warfarin, stop warfarin and give 4F-PCC plus intravenous vitamin K. PCC rapidly replaces vitamin K–dependent clotting factors; vitamin K supports sustained production of those factors after the PCC effect wanes. If 4F-PCC is unavailable, plasma may be used.

Recheck the INR and manage the hemorrhage urgently. In the specific case of intracranial hemorrhage with an INR of 4.2, the recommended strategy is to stop warfarin and give 4F-PCC plus intravenous vitamin K.

Factor Xa inhibitor bleeding

For uncontrolled, life-threatening bleeding while taking apixaban, stop apixaban and provide urgent supportive care and bleeding-source control. Andexanet alfa is no longer manufactured or sold in the United States; U.S. commercial sales ended December 22, 2025.

For severe factor Xa inhibitor–associated bleeding, 4F-PCC is commonly used under institutional protocols when clinically significant drug effect is likely. This is a nonspecific hemostatic strategy: PCC does not bind or remove apixaban and can increase thrombotic risk. Consider the last dose, kidney function, and a drug-specific anti-Xa level if available, but do not delay emergency treatment while waiting for a test.

Dabigatran-associated bleeding

For major bleeding associated with dabigatran, give idarucizumab 5 g intravenously as two 2.5-g doses. It specifically binds dabigatran.

Impaired renal function may prolong dabigatran exposure. After reversal, reassess the patient and relevant coagulation tests for recurrent anticoagulant effect. If clinically significant bleeding or drug effect persists, specialist-guided options may include another idarucizumab dose or dialysis.

Heparin and enoxaparin

Stop the anticoagulant. Protamine can rapidly neutralize unfractionated heparin; calculate its dose from the amount of heparin given recently and administer it slowly. Rapid infusion can cause severe hypotension or anaphylactoid reactions.

Protamine reverses enoxaparin only partially, and anti-factor Xa activity may remain. Ongoing bleeding may therefore require additional supportive care and bleeding-source control.

Antiplatelet-associated intracranial hemorrhage

For spontaneous intracranial hemorrhage in a patient taking aspirin who is not undergoing emergency surgery, platelet transfusion may be harmful and should not be given routinely. If emergency neurosurgery is required, platelet transfusion may be considered for aspirin-associated bleeding.

The effectiveness of desmopressin, with or without platelet transfusion, for limiting hematoma expansion is uncertain.